GlassScriptPhysician profile
Rose W Tse
NPI 1700816840
$1,119.23
in general payments reported to CMS, 2019-2025
8 companies · $253 in 2025
The $253 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $47.22 · 2021: $181 · 2023: $370 · 2024: $269 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $891.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $891.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $495.02 | 2021-2025 | Cobalt Dr Mri Surescan, Azure Xt Dr Mri Surescan, Linq II |
| Novartis Pharmaceuticals Corporation | $494.20 | 2020-2024 | |
| Boston Scientific Corporation | $40.61 | 2025 | General - Therapies |
| E.R. Squibb & Sons, L.L.C. | $28.32 | 2025 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $19.55 | 2020 | |
| Novo Nordisk INC | $14.66 | 2024 | Rybelsus, Ozempic |
| Arbor Pharmaceuticals, INC. | $13.76 | 2020 | |
| Esperion Therapeutics, INC. | $13.11 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rose Tse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.